Steven I. Sherman

56.7k total citations · 9 hit papers
262 papers, 34.8k citations indexed

About

Steven I. Sherman is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Surgery. According to data from OpenAlex, Steven I. Sherman has authored 262 papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Endocrinology, Diabetes and Metabolism, 55 papers in Oncology and 42 papers in Surgery. Recurrent topics in Steven I. Sherman's work include Thyroid Cancer Diagnosis and Treatment (178 papers), BRCA gene mutations in cancer (30 papers) and Thyroid and Parathyroid Surgery (26 papers). Steven I. Sherman is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (178 papers), BRCA gene mutations in cancer (30 papers) and Thyroid and Parathyroid Surgery (26 papers). Steven I. Sherman collaborates with scholars based in United States, France and Italy. Steven I. Sherman's co-authors include Bryan R. Haugen, Martin Schlumberger, Furio Pacini, Susan J. Mandel, R. Michael Tuttle, David L. Steward, Gerard M. Doherty, David S. Cooper, Leonard Wartofsky and Kathryn G. Schuff and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Steven I. Sherman

256 papers receiving 33.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

2015 10.0k citations Bryan R. Haugen, Erik K. Alexander et al. Thyroid profile →
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

2009 5.1k citations David S. Cooper, Gerard M. Doherty et al. Thyroid profile →
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce

2006 1.5k citations David S. Cooper, Gerard M. Doherty et al. Thyroid profile →
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

2015 1.4k citations Martin Schlumberger, Lori J. Wirth et al. profile →
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

2014 1.2k citations Marcia S. Brose, Barbara Jarząb et al. profile →
Cabozantinib in Progressive Medullary Thyroid Cancer

2013 850 citations Rossella Elisei, Martin Schlumberger et al. Journal of Clinical Oncology profile →
Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy

2006 507 citations Jacqueline Jonklaas, Kenneth B. Ain et al. Thyroid profile →
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

2011 445 citations Razelle Kurzrock, Steven I. Sherman et al. Journal of Clinical Oncology profile →
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

2021 156 citations Marcia S. Brose, Bruce Robinson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven I. Sherman United States	74	28.4k	14.1k	5.8k	4.4k	4.4k	262	34.8k
Furio Pacini Italy	74	30.5k 1.1×	15.4k 1.1×	4.7k 0.8×	5.0k 1.1×	3.9k 0.9×	258	35.2k
Martin Schlumberger France	93	39.8k 1.4×	19.9k 1.4×	9.0k 1.5×	7.1k 1.6×	6.3k 1.4×	387	50.2k
Electron Kebebew United States	69	9.8k 0.3×	7.7k 0.5×	4.3k 0.7×	862 0.2×	3.8k 0.9×	378	19.1k
Patrick C. Walsh United States	104	4.9k 0.2×	8.0k 0.6×	3.9k 0.7×	1.9k 0.4×	5.8k 1.3×	577	40.5k
W. Marston Linehan United States	113	3.8k 0.1×	7.9k 0.6×	7.5k 1.3×	2.9k 0.7×	22.2k 5.1×	586	44.9k
Per Hall Sweden	67	1.8k 0.1×	2.7k 0.2×	6.4k 1.1×	3.3k 0.7×	3.6k 0.8×	386	19.6k
Nicholas J. Vogelzang United States	89	2.2k 0.1×	10.1k 0.7×	17.2k 2.9×	5.5k 1.2×	8.4k 1.9×	701	41.8k
Alan W. Partin United States	94	2.2k 0.1×	6.5k 0.5×	4.9k 0.8×	2.8k 0.6×	7.6k 1.7×	657	40.3k
Jonathan I. Epstein United States	121	2.1k 0.1×	15.9k 1.1×	8.6k 1.5×	4.5k 1.0×	12.3k 2.8×	991	63.6k
Eric J. Small United States	86	3.3k 0.1×	2.5k 0.2×	14.3k 2.4×	6.7k 1.5×	8.9k 2.0×	613	35.7k

Countries citing papers authored by Steven I. Sherman

Since Specialization

Citations

This map shows the geographic impact of Steven I. Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven I. Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven I. Sherman more than expected).

Fields of papers citing papers by Steven I. Sherman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven I. Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven I. Sherman. The network helps show where Steven I. Sherman may publish in the future.

Co-authorship network of co-authors of Steven I. Sherman

This figure shows the co-authorship network connecting the top 25 collaborators of Steven I. Sherman. A scholar is included among the top collaborators of Steven I. Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven I. Sherman. Steven I. Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yedururi, Sireesha, Mimi I. Hu, Naifa L. Busaidy, et al.. (2024). Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 35(1). 6–17. 1 indexed citations

Murray, Suzanne, et al.. (2023). Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study. Thyroid Research. 16(1). 22–22. 2 indexed citations

Capdevila, Jaume, Jolanta Krajewska, Jorge Hernando, et al.. (2023). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 34(3). 347–359. 6 indexed citations

Kurzrock, Razelle, Douglas W. Ball, Marianna Zahurak, et al.. (2019). A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research. 25(18). 5475–5484. 19 indexed citations

Liyanarachchi, Sandya, Huiling He, Pamela Brock, et al.. (2019). Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid. 29(4). 530–539. 14 indexed citations

Bagheri‐Yarmand, Rozita, Krishna M. Sinha, Ling Li, et al.. (2018). Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress–Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Molecular Cancer Research. 17(3). 751–760. 26 indexed citations

Tang, Chad, Steven I. Sherman, Jun Weng, et al.. (2017). Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clinical Cancer Research. 23(6). 1414–1421. 27 indexed citations

Xu, Jian, William A. Murphy, Denái R. Milton, et al.. (2016). Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 101(12). 4871–4877. 22 indexed citations

Haugen, Bryan R., Erik K. Alexander, Keith C. Bible, et al.. (2015). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26(1). 1–133. 9985 indexed citations breakdown →

10.

Schlumberger, Martin, Barbara Jarząb, Maria E. Cabanillas, et al.. (2015). A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research. 22(1). 44–53. 184 indexed citations

11.

Cabanillas, Maria E., Marcia S. Brose, Jaymes Holland, Kimberly Ferguson, & Steven I. Sherman. (2014). A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer. Thyroid. 24(10). 1508–1514. 62 indexed citations

12.

Sherman, Steven I.. (2014). Molecular mechanisms in thyroid cancer biology. 12(7). 10–13. 1 indexed citations

13.

Elisei, Rossella, Martin Schlumberger, Stefan Müller, et al.. (2013). Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology. 31(29). 3639–3646. 850 indexed citations breakdown →

14.

McLeod, Donald S.A., David S. Cooper, Paul W. Ladenson, et al.. (2013). Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis. Thyroid. 24(1). 35–42. 103 indexed citations

15.

Schlumberger, Martin, Rossella Elisei, Lars Bastholt, et al.. (2009). Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology. 27(23). 3794–3801. 257 indexed citations

16.

Tsimberidou, Apostolia M., Christos Vaklavas, Sijin Wen, et al.. (2009). Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience. The Journal of Clinical Endocrinology & Metabolism. 94(11). 4423–4432. 28 indexed citations

17.

Sherman, Steven I.. (2009). Tyrosine kinase inhibitors and the thyroid. Best Practice & Research Clinical Endocrinology & Metabolism. 23(6). 713–722. 35 indexed citations

18.

Cooper, David S., Gerard M. Doherty, Bryan R. Haugen, et al.. (2009). Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 19(11). 1167–1214. 5125 indexed citations breakdown →

19.

Elliott, Danielle D., Steven I. Sherman, Naifa L. Busaidy, et al.. (2007). Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology. 39(1). 15–20. 30 indexed citations

20.

Sherman, Steven I. & Ann M. Gillenwater. (2003). Differentiated Thyroid Carcinoma. 144(2). 500–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact